Based on our combinatorial study comprising functional cancer genomics, human cancer specimens and biochemical approaches, we propose STAMBPL1 as a potential new predictive signature of EMT, and present a therapeutic opportunity of targeting STAMBPL1 to exhaust the EMT potential of cancer cells. Here, STAMBPL1 is linked to cancer.